Henry Schein/$HSIC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Henry Schein
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
- Ticker
- $HSIC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 25,000
- Headquarters
- Melville, United States
- Website
- www.henryschein.com
Henry Schein Metrics
BasicAdvanced
$9.3B
24.38
$3.43
0.81
-
Price and volume
Market cap
$9.3B
Beta
0.81
52-week high
$92.18
52-week low
$61.95
Average daily volume
1.1M
Financial strength
Current ratio
1.319
Quick ratio
0.55
Long term debt to equity
0.545
Total debt to equity
0.807
Interest coverage (TTM)
4.81%
Profitability
EBITDA (TTM)
1,080
Gross margin (TTM)
31.32%
Net profit margin (TTM)
2.96%
Operating margin (TTM)
5.76%
Effective tax rate (TTM)
23.66%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
4.39%
Return on equity (TTM)
8.85%
Valuation
Price to earnings (TTM)
24.384
Price to revenue (TTM)
0.716
Price to book
2.97
Price to tangible book (TTM)
-4.5
Price to free cash flow (TTM)
18.996
Free cash flow yield (TTM)
5.26%
Free cash flow per share (TTM)
4.404
Growth
Revenue change (TTM)
6.49%
Earnings per share change (TTM)
10.33%
3-year revenue growth (CAGR)
2.59%
10-year revenue growth (CAGR)
2.03%
3-year earnings per share growth (CAGR)
0.28%
10-year earnings per share growth (CAGR)
1.52%
What the Analysts think about Henry Schein
Analyst ratings (Buy, Hold, Sell) for Henry Schein stock.
Analyst projections of the future price of Henry Schein stock.
Bulls say / Bears say
Henry Schein’s second-quarter performance showed improving momentum: sales rose 6.7% and non-GAAP diluted EPS increased to $1.27 from $1.10. It raised 2026 guidance to 4.5% to 5.5% sales growth and $5.29 to $5.39 of non-GAAP EPS. (Business Wire)
The margin opportunity is becoming more tangible. Henry Schein is targeting more than $200 million of annual operating-income improvement over the next few years, with a $125 million run-rate by year-end 2026, while higher-margin specialty and technology businesses now generate nearly half of operating income. (The Motley Fool, Last10K)
Capital returns provide a potential per-share support while management executes its transformation. The company repurchased $325 million of shares in the first half, said leverage remained around 2.8 times, and described the stock as undervalued. (StockAnalysis)
Underlying growth remains moderate rather than rapid: first-half internal local-currency sales growth was 3.6%, while 2026 total sales guidance is 4.5% to 5.5%. Management also flagged softness in respiratory products, which represent about 15% of its medical business. (StockAnalysis, Business Wire)
The earnings improvement depends partly on a complex restructuring and value-creation programme. Henry Schein excludes restructuring and implementation costs from its adjusted guidance and says it cannot provide GAAP guidance, leaving a risk that reported profits and cash costs lag the headline targets. (The Motley Fool, Henry Schein)
Tariffs, freight and input-cost inflation could squeeze margins or force price increases on cost-conscious practices. Management said it will be difficult to sustain recent dental pricing beyond 2026, while the company’s latest filing warns of additional tariffs, retaliatory measures and supply-chain disruption. (StockAnalysis, Last10K)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.
Henry Schein Financial Performance
Revenues and expenses
Henry Schein Earnings Performance
Company profitability
Upcoming events
No upcoming events
Henry Schein News
AllArticlesVideos
Funds containing Henry Schein
AllEURGBPUSD
Fund name | Fund size | $HSIC weighting |
|---|---|---|
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.23% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.23% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.19% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.19% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.